SNTI is trading 5.1% up at $0.97 in pre-market, bouncing back from a 5.1% decline in the previous session as general risk-on sentiment drives follow-through momentum.
- No new company-specific headlines have been released today, suggesting the move is a technical recovery from the $0.92 level reached on June 23.
- The stock has seen significant volatility this year, including a spike of over 20% after its cancer therapy SENTI-202 received FDA RMAT designation.
- Bullish retail sentiment continues to surround the ticker following the recent regulatory milestones for its lead clinical program.